Literature DB >> 16948989

[Quantifying plasma levels of transforming growth factor beta1 in idiopathic pulmonary fibrosis].

María Molina-Molina1, Sergio Lario, Patricio Luburich, José Ramírez, María Teresa Carrión, Antoni Xaubet.   

Abstract

OBJECTIVE: Transforming growth factor ss1 (TGF-ss1) is one of the key profibrotic mediators in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The purpose of this study was to investigate the prognostic value of quantifying TGF-ss1 levels in patients with IPF. PATIENTS AND METHODS: We conducted a prospective study of 29 IPF patients and 27 healthy controls. Enzyme-linked immunosorbent assays were used to quantify TGF-ss1 levels.
RESULTS: Mean (SD) TGF-ss1 levels were significantly higher in the IPF patients than in the control subjects (11.1 [7.5] ng/mL vs 4 [2.4] ng/mL; P< .01). Weak inverse correlations were observed between TGF-ss1 levels and both forced vital capacity and total lung capacity. Thirteen IPF patients were evaluated at 8 (1.2) months (range, 5-9 months). The mean TGF-ss1 level was 18.2 (15) ng/mL and there were no significant differences with respect to the initial measurement of 11.1 (7.5) ng/mL. No correlation was observed between changes in respiratory function and changes in TGF-ss1 levels.
CONCLUSIONS: Although plasma levels of TGF-beta1 were high in the patients with IPF, they do not appear to be a useful prognostic marker of disease activity or therapeutic response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16948989     DOI: 10.1016/s1579-2129(06)60550-8

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  6 in total

Review 1.  A New Hypothetical Concept in Metabolic Understanding of Cardiac Fibrosis: Glycolysis Combined with TGF-β and KLF5 Signaling.

Authors:  Thanachai Methatham; Ryozo Nagai; Kenichi Aizawa
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

2.  Inhibition of Human Corneal Myofibroblast Formation.

Authors:  Xiaoqing Guo; Sriniwas Sriram; Jennifer A Tran; Audrey E K Hutcheon; James D Zieske
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-07-02       Impact factor: 4.799

3.  Tgf-β1 inhibits Cftr biogenesis and prevents functional rescue of ΔF508-Cftr in primary differentiated human bronchial epithelial cells.

Authors:  Steven M Snodgrass; Kristine M Cihil; Pamela K Cornuet; Michael M Myerburg; Agnieszka Swiatecka-Urban
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

4.  Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis.

Authors:  Esam H Alhamad; Joseph G Cal; Zahid Shakoor; Adel Almogren; Ahmad A AlBoukai
Journal:  BMC Med Genet       Date:  2013-07-01       Impact factor: 2.103

5.  Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations.

Authors:  Andréa Tavares Dantas; Sayonara Maria Calado Gonçalves; Anderson Rodrigues de Almeida; Rafaela Silva Guimarães Gonçalves; Maria Clara Pinheiro Duarte Sampaio; Kamila de Melo Vilar; Michelly Cristiny Pereira; Moacyr Jesus Barreto de Melo Rêgo; Ivan da Rocha Pitta; Claudia Diniz Lopes Marques; Angela Luzia Branco Pinto Duarte; Maira Galdino da Rocha Pitta
Journal:  Dis Markers       Date:  2016-11-14       Impact factor: 3.434

Review 6.  Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis.

Authors:  Kelly L Walton; Katharine E Johnson; Craig A Harrison
Journal:  Front Pharmacol       Date:  2017-07-14       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.